RT Journal Article
SR Electronic
T1 Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes
JF Clinical Diabetes
JO diaclin
FD American Diabetes Association
SP cd200022
DO 10.2337/cd20-0022
A1 Mehta, Sanjeev N.
A1 Tinsley, Liane J.
A1 Kruger, Davida
A1 Bode, Bruce
A1 Layne, Jennifer E.
A1 Huyett, Lauren M.
A1 Dryga, Kate
A1 Dumais, Bonnie
A1 Ly, Trang T.
A1 Laffel, Lori M.
YR 2020
UL http://clinical.diabetesjournals.org/content/early/2020/11/24/cd20-0022.abstract
AB Continuous subcutaneous insulin infusion (CSII) treatment may improve long-term glycemic outcomes and enhance quality of life compared with a multiple daily injection (MDI) insulin regimen for people with type 1 diabetes. As the number of people treated with CSII via a tubeless insulin pump is increasing, there is growing interest in the long-term glycemic outcomes of this treatment option across diverse populations. This multicenter, retrospective study evaluated glycemic control in 156 adults with type 1 diabetes initiating tubeless insulin pump therapy following transition from either MDI or CSII with a tubed insulin pump. In this study, use of the tubeless insulin pump over 12 months was associated with significant improvement in A1C in adults with type 1 diabetes, most notably in those with an A1C ≥9.0% and those previously treated with MDI.